Paper25706232
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Osinusi A and 27 others. JAMA, 2015. Cited by 167 papers, by iCite.
Cite this record
ConductScience Library. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Papers, record 25706232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25706232
- Disease
- HIV infectious disease454 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Benzimidazoles | Major topic |
| Fluorenes | Major topic |
| HIV Infections | Major topic |
| Hepacivirus | Major topic |
| Hepatitis C, Chronic | Major topic |
| Uridine Monophosphate | Major topic |
| Administration, Oral | |
| Adult | |
| Coinfection | |
| Drug Therapy, Combination | |
| Female | |
| Genotype | |
| Humans | |
| Male | |
| Middle Aged | |
| Myalgia | |
| RNA, Viral | |
| Sofosbuvir | |
| Treatment Outcome | |
| Viral Load |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 BC010686 | Intramural NIH HHS | United States | Z01BC010686 | PubMed | NIH RePORTER |
| Z01 AI000390 | Intramural NIH HHS | United States | Z01AI000390 | PubMed | NIH RePORTER |
| ZID BC011242 | Intramural NIH HHS | United States | ZIDBC011242 | PubMed and NIH | NIH RePORTER |
| HHSN261200800001C | CCR NIH HHS | United States | PubMed | PubMed | |
| HHSN261200800001E | NCI NIH HHS | United States | PubMed | PubMed | |
| ZIACL009010 | NIH | NIH RePORTER | |||
| ZIACL040015 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01878799 | Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 25705993 | Hepatitis C and HIV co-infection: closing the gaps. | https://conductscience.org/library/papers/25705993 | PubMed |
| Comment in | 26172899 | Drug-Drug Interactions in Patients Co-infected With HCV and HIV. | https://conductscience.org/library/papers/26172899 | PubMed |
| Comment in | 26172900 | Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply. | https://conductscience.org/library/papers/26172900 | PubMed |
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24725238 | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24725238 | PubMed |
| 2 | 19684573 | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. | Nature | 2009 | https://conductscience.org/library/papers/19684573 | PubMed |
| 3 | 22820790 | Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. | JAMA | 2012 | https://conductscience.org/library/papers/22820790 | PubMed |
| 4 | 23291588 | A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. | Nat Genet | 2013 | https://conductscience.org/library/papers/23291588 | PubMed |
| 5 | 23685940 | Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. | Ann Intern Med | 2013 | https://conductscience.org/library/papers/23685940 | PubMed |
| 6 | 19414839 | A new equation to estimate glomerular filtration rate. | Ann Intern Med | 2009 | https://conductscience.org/library/papers/19414839 | PubMed |
| 7 | 20831874 | Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. | J Theor Biol | 2010 | https://conductscience.org/library/papers/20831874 | PubMed |
| 8 | 23982366 | Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. | JAMA | 2013 | https://conductscience.org/library/papers/23982366 | PubMed |
| 9 | 20723038 | A perspective on modelling hepatitis C virus infection. | J Viral Hepat | 2010 | https://conductscience.org/library/papers/20723038 | PubMed |
| 10 | 16908797 | Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. | Arch Intern Med | 2006 | https://conductscience.org/library/papers/16908797 | PubMed |
| 11 | 24720702 | Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24720702 | PubMed |
| 12 | 15282352 | Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15282352 | PubMed |
| 13 | 23768747 | Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. | Lancet Infect Dis | 2013 | https://conductscience.org/library/papers/23768747 | PubMed |
| 14 | 23390302 | Current management of hepatitis C virus infection in patients with HIV co-infection. | J Infect Dis | 2013 | https://conductscience.org/library/papers/23390302 | PubMed |
| 15 | 15598915 | Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. | JAMA | 2004 | https://conductscience.org/library/papers/15598915 | PubMed |
| 16 | 15282351 | Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15282351 | PubMed |
| 17 | 25192745 | Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. | Clin Infect Dis | 2014 | https://conductscience.org/library/papers/25192745 | PubMed |
| 18 | 24725239 | Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. | N Engl J Med | 2014 | https://conductscience.org/library/papers/24725239 | PubMed |
| 19 | 23172780 | Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. | Hepatology | 2013 | https://conductscience.org/library/papers/23172780 | PubMed |
| 20 | 23499158 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. | Lancet Infect Dis | 2013 | https://conductscience.org/library/papers/23499158 | PubMed |
Cited by99
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41018711 | Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/41018711 | PubMed |
| 40006924 | Hepatitis C Virus Resistance-Associated Substitutions in Mexico. | Viruses | 2025 | https://conductscience.org/library/papers/40006924 | PubMed |
| 36777459 | Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection. | HIV AIDS (Auckl) | 2023 | https://conductscience.org/library/papers/36777459 | PubMed |
| 36562643 | Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. | J Int AIDS Soc | 2022 | https://conductscience.org/library/papers/36562643 | PubMed |
| 36514496 | Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine. | JGH Open | 2022 | https://conductscience.org/library/papers/36514496 | PubMed |
| 36233234 | Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36233234 | PubMed |
| 35334612 | Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/35334612 | PubMed |
| 34845874 | Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. | J Korean Med Sci | 2021 | https://conductscience.org/library/papers/34845874 | PubMed |
| 34222417 | Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults. | World J Clin Cases | 2021 | https://conductscience.org/library/papers/34222417 | PubMed |
| 34205966 | Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? | Viruses | 2021 | https://conductscience.org/library/papers/34205966 | PubMed |
| 34157923 | An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. | Expert Opin Pharmacother | 2021 | https://conductscience.org/library/papers/34157923 | PubMed |
| 33871393 | Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. | J Chin Med Assoc | 2021 | https://conductscience.org/library/papers/33871393 | PubMed |
| 33072543 | Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV. | Adv Pharm Bull | 2020 | https://conductscience.org/library/papers/33072543 | PubMed |
| 33050486 | Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33050486 | PubMed |
| 32915202 | DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32915202 | PubMed |
| 32308542 | Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. | Int J Med Sci | 2020 | https://conductscience.org/library/papers/32308542 | PubMed |
| 31922124 | Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. | EClinicalMedicine | 2020 | https://conductscience.org/library/papers/31922124 | PubMed |
| 31504644 | Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-ΔG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. | J Infect Dis | 2020 | https://conductscience.org/library/papers/31504644 | PubMed |
| 31413526 | Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/31413526 | PubMed |
| 31114268 | Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial. | Infect Drug Resist | 2019 | https://conductscience.org/library/papers/31114268 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| IFNL3 | 282617 | PubTator's text mining | https://conductscience.org/library/genes/282617 | NCBI Gene |
| IFNL4 | 101180976 | PubTator's text mining | https://conductscience.org/library/genes/101180976 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| SOFOSBUVIR | CHEMBL1259059 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1259059 | ChEMBL |
| LEDIPASVIR | CHEMBL2374220 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2374220 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25706232
GET https://conductscience.org/api/papers/v1/25706232/authors?page=2